The 'noradrenaline transporter' or 'NAT' is a
monoamine transporter that transports the
neurotransmitter noradrenaline from the
synapse back to its vesicles for storage until later use. It also appears to transport the
neurotransmitter dopamine in the same way, but to a lesser degree.
Certain
antidepressant medications act to raise noradrenaline, such as the
SNRIs and the
tricyclic antidepressants (TCAs). In other words, these medications prevent the noradrenaline transporter from doing its job. Noradrenaline therefore remains in the
synapse longer, allowing it to reach more normal levels. Since the noradrenaline transporter is also thought to transport dopamine to some extent,
SNRIs would also raise dopamine levels in the synapse.
A loss of function mutation in the noradrenaline transporter has been associated with
postural orthostatic tachycardia syndrome in one kindred.
[1] An
epigenetic mechanism (hypermethylation of CpG islands in the NET gene promoter region
[2]) that results in reduced expression of the noradrenaline transporter and consequently a phenotype of impaired neuronal reuptake of
noradrenaline has been implicated in both postural orthostatic tachycardia syndrome and
panic disorder.
See also
★
Neurotransmitter transporter
References
1. Orthostatic intolerance and tachycardia associated with norepinephrine-transporter deficiency, Shannon J, Flattem N, Jordan J, Jacob G, Black B, Biaggioni I, Blakely R, Robertson D, , , N Engl J Med, 2000
2. The neuronal noradrenaline transporter, anxiety and cardiovascular disease, Esler M, Alvarenga M, Pier C, Richards J, El-Osta A, Barton D, Haikerwal D, Kaye D, Schlaich M, Guo L, Jennings G, Socratous F, Lambert G, , , J Psychopharmacol, 2006
External links
★